GlassScriptPhysician profile
David B Trowbridge
NPI 1134215809
$1,395.65
in general payments reported to CMS, 2019-2025
14 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $42.91 · 2021: $82.60 · 2022: $153 · 2023: $212 · 2024: $431 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $214.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $379.69 | 2020-2025 | |
| Abbvie INC. | $303.83 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $242.92 | 2020-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $182.25 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $58.56 | 2019-2023 | |
| Organon LLC | $58.17 | 2021-2025 | Hadlima |
| Genzyme Corporation | $41.45 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $27.58 | 2019-2021 | |
| Celltrion USA INC. | $24.47 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $21.84 | 2023 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.66 | 2022 | |
| Shire North American Group INC | $20.49 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.74 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,973.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Trowbridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.